Valuation : Sorrento Therapeutics, Inc.

Market Cap 67.15M 57.86M 54.25M 49.52M 93.29M 6.42B 93.59M 644M 251M 3.24B 252M 247M 10.74B P/E 2021
-3.2x
P/E 2022 -0.65x
Enterprise Value 152M 131M 123M 112M 211M 14.5B 211M 1.45B 567M 7.32B 569M 557M 24.26B EV / Sales 2021
29.1x
EV / Sales 2022 7.89x
Free-Float
98.65%
Yield 2021 *
-
Yield 2022 -
1 week-37.50%
6 months-68.75%
Current year-80.77%
1 week 0
Extreme 0.0004
0
1 month 0
Extreme 0.0004
0.01
Current year 0
Extreme 1.0E-6
0.01
1 year 0
Extreme 1.0E-6
0.1
3 years 0
Extreme 1.0E-6
0.25
5 years 0
Extreme 1.0E-6
9.31
10 years 0
Extreme 1.0E-6
19.39
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2011
Chief Tech/Sci/R&D Officer - 01/03/2022
General Counsel - -
Director TitleAgeSince
Chairman 61 01/08/2017
Date Insider Type Main position Quantity % Market Cap.
17/03/23 Option

Chief Executive Officer

19,695 0.0042%
15/12/22 Free

Chief Executive Officer

1,500,000 0.3179%
02/12/22 Option

Chief Executive Officer

505 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-37.50%-91.67%-99.64% 272K
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -1.82%-5.48%+42.83%+162.40% 28.19B
Weighted average by Cap. -1.93%-1.50%+53.73%+151.51%

Financials

2021 2022
Net sales 52.9M 45.59M 42.74M 39.02M 73.5M 5.06B 73.74M 507M 198M 2.55B 199M 194M 8.46B 62.84M 54.15M 50.77M 46.35M 87.31M 6.01B 87.58M 602M 235M 3.03B 236M 231M 10.05B
Net income -428M -369M -346M -316M -595M -40.94B -597M -4.11B -1.6B -20.66B -1.61B -1.57B -68.52B -573M -494M -463M -422M -796M -54.75B -798M -5.49B -2.14B -27.64B -2.15B -2.1B -91.64B
Net Debt 111M 95.39M 89.43M 81.64M 154M 10.58B 154M 1.06B 414M 5.34B 416M 407M 17.71B 84.53M 72.84M 68.29M 62.34M 117M 8.08B 118M 810M 316M 4.08B 317M 310M 13.52B
Logo Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. It is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist. The Company’s proprietary fully human G-MAB antibody library and ACEA small molecule library are the pipeline of new solutions for cancer. Its diagnostics platforms include the COVIMARK lateral flow antigen test and the VIREX platform.
Employees
949
Date Price Change Volume
28/08/26 $0.000500 0.00% 26,750
27/08/26 $0.000500 -44.44% 103,292
26/08/26 $0.000900 +28.57% 135,982
25/08/26 $0.000700 -12.50% 332,415
24/08/26 $0.000800 0.00% 88,367
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SRNE Stock